Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma

I-Ting Wang; Hsiao-Lin Chen; Wei-Ming Huang; Nai-Jung Chiang; Li-Jiuan Shen; Chen-Han Chueh; Yi-Wen Tsai

doi:10.1186/s12962-025-00713-w

Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma

Cost Eff Resour Alloc. 2026 Feb 10. doi: 10.1186/s12962-025-00713-w. Online ahead of print.

Authors

I-Ting Wang^#¹, Hsiao-Lin Chen^#¹, Wei-Ming Huang^#^{1

2}, Nai-Jung Chiang^{3

4}, Li-Jiuan Shen^{5

6

7}, Chen-Han Chueh⁸, Yi-Wen Tsai^{9

10

11}

Affiliations

¹ Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
² Medical AI Development Center, Taipei Veterans General Hospital, Taipei, Taiwan.
³ Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
⁴ School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁵ School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
⁶ Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
⁷ Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
⁸ Herbert Wertheim School of Public Health, University of California San Diego, San Diego, CA, USA. chchueh@health.ucsd.edu.
⁹ Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.
¹⁰ Medical AI Development Center, Taipei Veterans General Hospital, Taipei, Taiwan. ywtsai@nycu.edu.tw.
¹¹ College of Pharmaceutical Science, National Yang Ming Chiao Tung University, Taipei, Taiwan. ywtsai@nycu.edu.tw.

^# Contributed equally.

PMID: 41668195
DOI: 10.1186/s12962-025-00713-w

No abstract available

Keywords: FGFR2; Conditional listing; Cost-effectiveness analysis; Economic evaluation; Health technology reassessment; Intrahepatic cholangiocarcinoma; Pemigatinib; Provisional payment; Targeted therapy.